| Lifetime medical costs of obesity: prevention no cure for increasing health expenditure PHM van Baal, JJ Polder, GA De Wit, RT Hoogenveen, TL Feenstra, ... PLoS medicine 5 (2), e29, 2008 | 363 | 2008 |
| When is it too expensive? Cost-effectiveness thresholds and health care decision-making W Brouwer, P van Baal, J van Exel, M Versteegh The European Journal of Health Economics 20 (2), 175-180, 2019 | 140 | 2019 |
| Mortality risk associated with disability: a population-based record linkage study IM Majer, WJ Nusselder, JP Mackenbach, B Klijs, PHM Van Baal American journal of public health 101 (12), e9-e15, 2011 | 129 | 2011 |
| Exploring the influence of proximity to death on disease‐specific hospital expenditures: A carpaccio of red herrings A Wong, PHM van Baal, HC Boshuizen, JJ Polder Health economics 20 (4), 379-400, 2011 | 123 | 2011 |
| Cost-effectiveness of lifestyle modification in diabetic patients MAM Jacobs-van der Bruggen, PH van Baal, RT Hoogenveen, ... Diabetes care 32 (8), 1453-1458, 2009 | 116 | 2009 |
| Standardizing the inclusion of indirect medical costs in economic evaluations PHM van Baal, A Wong, LCJ Slobbe, JJ Polder, WBF Brouwer, GA de Wit Pharmacoeconomics 29, 175-187, 2011 | 114 | 2011 |
| Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? DR Rappange, PHM van Baal, NJA van Exel, TL Feenstra, FFH Rutten, ... Pharmacoeconomics 26, 815-830, 2008 | 105 | 2008 |
| Diabetes mellitus in the Netherlands: estimate of the current disease burden and prognosis for 2025 CA Baan, PH Van Baal, MA Jacobs-Van der Bruggen, H Verkley, MJ Poos, ... Nederlands tijdschrift voor geneeskunde 153, A580-A580, 2009 | 97* | 2009 |
| DYNAMO-HIA–a dynamic modeling tool for generic health impact assessments SK Lhachimi, WJ Nusselder, HA Smit, P van Baal, P Baili, K Bennett, ... PloS one 7 (5), e33317, 2012 | 92 | 2012 |
| Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’cost–utility ratio PHM Van Baal, TL Feenstra, RT Hoogenveen, G Ardine de Wit, ... Health Economics 16 (4), 421-433, 2007 | 90 | 2007 |
| Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity PHM Van Baal, RT Hoogenveen, AG de Wit, HC Boshuizen Population Health Metrics 4, 1-13, 2006 | 85 | 2006 |
| Disability weights for comorbidity and their influence on health-adjusted life expectancy PHM Van Baal, N Hoeymans, RT Hoogenveen, AG de Wit, GP Westert Population Health Metrics 4, 1-7, 2006 | 77 | 2006 |
| Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions RT Hoogenveen, PHM van Baal, HC Boshuizen Mathematical medicine and biology: a journal of the IMA 27 (1), 1-19, 2010 | 75 | 2010 |
| FUTURE COSTS, FIXED HEALTHCARE BUDGETS, AND THE DECISION RULES OF COST-EFFECTIVENESS ANALYSIS P Baal, D Meltzer, W Brouwer Health Economics, 2014 | 72 | 2014 |
| Modeling and forecasting health expectancy: theoretical framework and application IM Majer, R Stevens, WJ Nusselder, JP Mackenbach, PHM van Baal Demography 50 (2), 673-697, 2013 | 72 | 2013 |
| To die with or from heart failure: a difference that counts: is heart failure underrepresented in national mortality statistics? PM Engelfriet, RT Hoogenveen, HC Boshuizen, PHM van Baal European journal of heart failure 13 (4), 377-383, 2011 | 72 | 2011 |
| The DYNAMO-HIA model: an efficient implementation of a risk factor/chronic disease Markov model for use in Health Impact Assessment (HIA) HC Boshuizen, SK Lhachimi, PHM van Baal, RT Hoogenveen, HA Smit, ... Demography 49, 1259-1283, 2012 | 69 | 2012 |
| Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: the role of time since cessation RT Hoogenveen, PHM van Baal, HC Boshuizen, TL Feenstra Cost effectiveness and resource allocation 6, 1-15, 2008 | 69 | 2008 |
| Increasing tobacco taxes: a cheap tool to increase public health PHM van Baal, WBF Brouwer, RT Hoogenveen, TL Feenstra Health Policy 82 (2), 142-152, 2007 | 69 | 2007 |
| A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending P van Baal, M Perry‐Duxbury, P Bakx, M Versteegh, E Van Doorslaer, ... Health economics 28 (1), 87-100, 2019 | 65 | 2019 |
Werner B.F. BrouwerProfessor of Health Economics, Erasmus School of Health Policy & Management, Erasmus UniversityDirección de correo verificada de eshpm.eur.nl